Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07008001
Recruiting Not applicable

Assessment of DOT Spectacles in Chinese Children Extension

NCT07008001 · tracked via the Priya Life Science China tracker
Sponsor
SightGlass Vision, Inc
Phase
Not applicable
Started
2025-08-01
Last updated
2025-12-29

Condition(s) studied

Juvenile MyopiaMyopia

Investigational drug(s) / intervention(s)

Novel spectacle lens design

Novel spectacle lens design: Use of spectacle lenses may reduce the rate of progression of juvenile myopia

Study summary

This is a randomized, controlled, open-label, evaluator-blinded, multicenter, clinical trial of 12-months duration to evaluate the continued safety and efficacy of Diffusion Optics Technology (DOT) spectacle lenses in reducing the progression of juvenile myopia in children of Chinese origin.

Eligibility

Sex
ALL
Min age
8 Years
Max age
16 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Previously a successfully completed participant in the CATHAY study (NCT05562622) 2. Agree to wear the assigned spectacles constantly except for sleeping, swimming, or other activities in which spectacle wear would be dangerous or otherwise not possible (minimum of 10 hours per day) 3. Willingness to participate in the trial for 12 months without contact lens wear or any other myopia management intervention 4. The subject's parent(s) or legal guardian(s) must read, understand and sign the Statement of Informed Consent and receive a fully executed copy of the form Exclusion Criteria: 1\. Known allergy to proparacaine, tetracaine, or tropicamide or cyclopentolate

Primary outcome measure(s)

  • Axial length Group I — 12 months
    Change in axial length from baseline to 36 months
  • Axial length Group II — 12 months
    Change in axial length from baseline to 12 months

Trial sites (5)

FacilityCityRegionStatus
Aier Eye Hospital Changsha China Recruiting
West China Hospital Chengdu China Recruiting
Zhongshan Ophthalmic Center Guangzhou China Not Yet Recruiting
Fudan University EENT Shanghai China Recruiting
Tianjin Eye Hospital Tianjin China Recruiting

More SightGlass Vision, Inc. trials in China

Assessment of DOT Spectacles in Chinese Children Active, not recruiting

Other trials for the same condition

School-based Myopia Prevention Trial for Children With Adequate Hyperopic Reserve Recruiting
Auricular Acupressure Reduces Rebound Effects After Discontinuation of Atropine Starting soon
Minimum Power and Frequency of Repeated Low-level Red-light to Effectively Control Myopia Progression Recruiting
Comparison of Low- Versus High-Level Angle Kappa Compensation Strategies in SMILE Using the VisuMax 800: A Randomized Clinical Trial Recruiting
A Study to Evaluate the Safety and Efficacy of the Bausch + Lomb Myopia Control Lens for the Correction of Myopic Ametropia and Slowing the Progression of Myopia in Children Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07008001 on ClinicalTrials.gov ↗ ← All trials in China